Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TNGX by emailGet an email when TNGX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TNGX, unsubscribe in one click. Privacy
📣 What TNGX Says Is Next
in 2026 · “The Company is currently reviewing the registrational strategy for vopimetostat and intends to provide details when combination data are shared in 2026.”
Company press release, May 13, 2026 · SEC filing
in 2026 · “Initial phase 1/2 data are anticipated in 2026 and may inform a path to a pivotal trial in 1L pancreatic cancer.”
Company press release, May 13, 2026 · SEC filing
in 2026 · “Initial phase 1/2 data are anticipated in 2026 and may inform an innovative development path to a pivotal trial in 1L pancreatic cancer.”
Company press release, Mar 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TNGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.